SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (595)11/19/2001 6:53:52 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3559
 
J Clin Invest, November 2001, Volume 108, Number 10, 1459-1467
Copyright ©2001 by the American Society for Clinical Investigation

--------------------------------------------------------------------------------

Article

Suppressor of cytokine signaling-3 is a biomechanical stress–inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways
Hideo Yasukawa1, Masahiko Hoshijima1, Yusu Gu1, Tomoyuki Nakamura1, Sylvain Pradervand1, Toshikatsu Hanada2,3, Yasushi Hanakawa4, Akihiko Yoshimura2, John Ross, Jr.1 and Kenneth R. Chien1
1 University of California San Diego (UCSD)–Salk Program in Molecular Medicine, UCSD Institute of Molecular Medicine, and Department of Medicine, University of California San Diego, La Jolla, California, USA 2 Division of Molecular and Cellular Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan 3 Division of Molecular Genetics, Institute of Life Science, Kurume University, Kurume, Japan 4 Department of Dermatology, Ehime University School of Medicine, Ehime, Japan

Address correspondence to: Kenneth R. Chien, UCSD Institute of Molecular Medicine, University of California San Diego, La Jolla, California 92093-0613C, USA. Phone: (858) 534-6835; Fax: (858) 534-8081; E-mail: kchien@ucsd.edu.

Received for publication August 9, 2001, and accepted in revised form October 1, 2001.

The gp130 cytokine receptor activates a cardiomyocyte survival pathway during the transition to heart failure following the biomechanical stress of pressure overload. Although gp130 activation is observed transiently during transverse aortic constriction (TAC), its mechanism of inactivation is largely unknown in cardiomyocytes. We show here that suppressor of cytokine signaling 3 (SOCS3), an intrinsic inhibitor of JAK, shows biphasic induction in response to TAC. The induction of SOCS3 was closely correlated with STAT3 phosphorylation, as well as the activation of an embryonic gene program, suggesting that cardiac gp130-JAK signaling is precisely controlled by this endogenous suppressor. In addition to its cytoprotective action, gp130-dependent signaling induces cardiomyocyte hypertrophy. Adenovirus-mediated gene transfer of SOCS3 to ventricular cardiomyocytes completely suppressed both hypertrophy and antiapoptotic phenotypes induced by leukemia inhibitory factor (LIF). To our knowledge, this is the first clear evidence that these two separate cardiomyocyte phenotypes induced by gp130 activation lie downstream of JAK. Three independent signaling pathways, STAT3, MEK1-ERK1/2, and AKT activation, that are coinduced by LIF stimulation were completely suppressed by SOCS3 overexpression. We conclude that SOCS3 is a mechanical stress–inducible gene in cardiac muscle cells and that it directly modulates stress-induced gp130 cytokine receptor signaling as the key molecular switch for a negative feedback circuit for both myocyte hypertrophy and survival.